Immunization

Researchers explored ideas of simplifying the vaccination process to yield higher rates of adult immunization, similar to that of the COVID-19 pandemic.

Researchers aimed to identify the barriers impeding HPV vaccine uptake since 2019 among US mid-adults aged 27 to 45.

Check out this list of our top 5 most read immunization stories from the year 2024.

Researchers reviewed Medicaid policies to understand vaccine coverage and reimbursement rates among physicians and pharmacists.

Researchers presented the community-wide benefits of a collaborative pharmacy-driven vaccine clinic in an urban setting.

Researchers analyzed the expansion of HPV vaccination for mid-adults defined as people 26 years or older with increased HPV risk.

Researchers addressed vaccine effectiveness for individuals with direct household contacts that reported influenza.

Public health and infectious disease experts offered their perspectives on the 2024 US bird flu outbreak and its potential of becoming a greater public health crisis.

Adam J. James, PharmD, joined Drug Topics to discuss his career journey as a chain pharmacist.

Drug Topics sat down with Adam J. James, PharmD, to discuss his journey from chain pharmacist to innovation leader at Rite Aid."

After shared decision making with their community pharmacist, patients were more likely to receive an RSV vaccine.

Lauren Angelo, PharmD, MBA, discusses effective ways pharmacists can educate and encourage their communities on the importance of flu vaccination.

Ruth Carrico, PhD, DNP, APRN, sat down with Drug Topics to discuss the importance of COVID-19 and influenza vaccination.

Ruth Carrico, PhD, DNP, APRN, discussed declining influenza and COVID-19 vaccination rates and how it has created a looming threat for public health officials.

Ruth Carrico, PhD, DNP, APRN, discussed the importance of annual vaccination and overall health awareness and literacy during the winter flu season.

Before marketing your pharmacy’s immunizations services, check out these takeaways from NCPA.

A second immunization session focused on updates in meningococcal disease, HPV, and Mpox.

The first of a 2-part presentation focused on vaccines for COVID-19, flu, RSV, and pneumococcal disease.

As the H5 bird flu outbreak gradually impacts human health in the US, health care experts weighed in on possibilities of a future vaccine.

Analyzing outcomes from the COVID-19, influenza, and pneumococcal vaccines, researchers explored the effectiveness and patient hesitancy surrounding each vaccine.

The new recommendations suggest vaccination at age 50, rather than age 65.

Abrysvo is the only RSV vaccine approved for use in this age group.

Researchers explored the overall efficacy of various pediatric vaccines and their effects on antibiotic use, while also addressing vaccine hesitancy among parents.

Pharmacist education can positively impact patient counseling around vaccinations in older adults.

Vaccination against HPV can prevent thousands of cases of cancer each year.

Three RSV vaccines are currently FDA approved for use in adults aged 60 or older.

Cases of meningococcal disease currently exceed prepandemic levels.

Dozens of presentations at IDWeek 2024 focused on available immunizations, such as those for COVID-19, respiratory syncytial virus, and flu.

Researchers addressed the prevalence of RSV and its associations with immunization, infection, and hospitalization amongst older adults.

GSK’s respiratory syncytial virus vaccine continued to provide adults aged 60 years and older with clinically meaningful protection.